890 related articles for article (PubMed ID: 27330279)
1. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
Yang S; Zhao J; Sun X
Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
[TBL] [Abstract][Full Text] [Related]
2. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
Lu X; Sun X
Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM; Noureddine BN; Bashshur ZF
Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
[TBL] [Abstract][Full Text] [Related]
4. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.
Cho M; Barbazetto IA; Freund KB
Am J Ophthalmol; 2009 Jul; 148(1):70-8.e1. PubMed ID: 19403115
[TBL] [Abstract][Full Text] [Related]
5. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
6. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
7. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors.
Mehta H; Tufail A; Daien V; Lee AY; Nguyen V; Ozturk M; Barthelmes D; Gillies MC
Prog Retin Eye Res; 2018 Jul; 65():127-146. PubMed ID: 29305324
[TBL] [Abstract][Full Text] [Related]
9. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.
Gemenetzi M; Lotery AJ; Patel PJ
Eye (Lond); 2017 Jan; 31(1):1-9. PubMed ID: 27716750
[TBL] [Abstract][Full Text] [Related]
10. Defining response to anti-VEGF therapies in neovascular AMD.
Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
[TBL] [Abstract][Full Text] [Related]
11. [Anti-VEGF therapy resistance in neovascular age-related macular degeneration].
Budzinskaya MV; Plyukhova AA; Sorokin PA
Vestn Oftalmol; 2017; 133(4):103-108. PubMed ID: 28980574
[TBL] [Abstract][Full Text] [Related]
12. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
13. The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.
Teo KYC; Gillies M; Fraser-Bell S
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30177632
[TBL] [Abstract][Full Text] [Related]
14. Current advances in the treatment of neovascular age-related macular degeneration.
Villegas VM; Aranguren LA; Kovach JL; Schwartz SG; Flynn HW
Expert Opin Drug Deliv; 2017 Feb; 14(2):273-282. PubMed ID: 27434329
[TBL] [Abstract][Full Text] [Related]
15. Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration.
Falavarjani KG; Sadda SR
Curr Pharm Des; 2017; 23(4):535-541. PubMed ID: 27981904
[TBL] [Abstract][Full Text] [Related]
16. Evolving multidimensional pharmacological approaches to CNV therapy in AMD.
Ehrenberg M; Benny O
Curr Eye Res; 2018 Feb; 43(2):147-154. PubMed ID: 29111834
[TBL] [Abstract][Full Text] [Related]
17. Preferred therapies for neovascular age-related macular degeneration.
Chiang A; Regillo CD
Curr Opin Ophthalmol; 2011 May; 22(3):199-204. PubMed ID: 21427571
[TBL] [Abstract][Full Text] [Related]
18. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF agents for age-related macular degeneration.
Ozkiris A
Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
